Literature DB >> 18929151

North Central Cancer Treatment Group--achievements and perspectives.

Axel Grothey1, Alex A Adjei, Steve R Alberts, Edith A Perez, Kurt A Jaeckle, Charles L Loprinzi, Daniel J Sargent, Jeff A Sloan, Jan C Buckner.   

Abstract

The North Central Cancer Treatment Group (NCCTG) was founded in 1977 as a regional cooperative group to allow cancer patients in the upper Midwest of the United States to gain access to clinical trials in oncology by establishing a network of community oncology practices with one academic research base, the Mayo Clinic. Since then, the NCCTG has grown into an international cooperative group with 43 members in 33 US states and Canada. This article details 30 years of achievements of the NCCTG, including important scientific contributions from disease-specific and treatment modality committees, the cancer control program, patient-reported outcomes and quality-of-life research, and biostatisticians that support the NCCTG's specific aims: to improve the duration and quality of life of cancer patients, to enhance our understanding of the biological consequences of cancer and its treatment, and to improve methods for clinical trial conduct.

Entities:  

Mesh:

Year:  2008        PMID: 18929151      PMCID: PMC6158781          DOI: 10.1053/j.seminoncol.2008.07.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  130 in total

1.  A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.

Authors:  E A Perez; D W Hillman; P J Stella; J E Krook; L C Hartmann; T R Fitch; A K Hatfield; J A Mailliard; S Nair; C G Kardinal; J N Ingle
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

Review 2.  Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores.

Authors:  Marlene H Frost; Amy E Bonomi; Carol Estwing Ferrans; Gilbert Y Wong; Ron D Hays
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

3.  Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

Authors:  Paul D Brown; Ashley W Jensen; Sara J Felten; Karla V Ballman; Paul L Schaefer; Kurt A Jaeckle; Jane H Cerhan; Jan C Buckner
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

4.  Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

Authors:  Edith A Perez; Vera J Suman; Kendrith M Rowland; James N Ingle; Muhammad Salim; Charles L Loprinzi; Patrick J Flynn; James A Mailliard; Carl G Kardinal; James E Krook; Abby R Thrower; Daniel W Visscher; Robert B Jenkins
Journal:  Clin Breast Cancer       Date:  2005-12       Impact factor: 3.225

Review 5.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

6.  Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer.

Authors:  Steven E Schild; Philip J Stella; Susan M Geyer; James A Bonner; Randolph S Marks; William L McGinnis; Steven P Goetz; Steven A Kuross; James A Mailliard; John W Kugler; Paul L Schaefer; James R Jett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

7.  Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.

Authors:  C L Loprinzi; S A Kuross; J R O'Fallon; D H Gesme; J B Gerstner; R M Rospond; C D Cobau; R M Goldberg
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

8.  Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.

Authors:  C L Loprinzi; R M Goldberg; J Q Su; J A Mailliard; S A Kuross; A W Maksymiuk; J W Kugler; J R Jett; C Ghosh; D M Pfeifle
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

9.  Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis.

Authors:  Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

10.  A comparison of laparoscopically assisted and open colectomy for colon cancer.

Authors:  Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.